Truist Initiates Buy Rating on Genmab, Targeting $40 Amid Promising Pipeline
Truist assumes Genmab stock coverage with buy rating on pipeline
Image: Investing Australia
Truist Securities has begun coverage of Genmab A/S with a Buy rating and a price target of $40. The stock, currently at $26.89, has significant upside potential. Genmab's pipeline includes key assets expected to deliver important results by 2026, indicating strong long-term value creation.
- 01Truist lowered its price target for Genmab from $48 to $40, reflecting a focus on the company's transition to a commercially driven platform.
- 02Genmab's pipeline includes three lead assets with up to seven key readouts anticipated by 2026.
- 03The company reported a 25% revenue increase in Q1 2026, driven by strong sales of proprietary medicines like EPKINLY and TIVDAK.
- 04Genmab's gross profit margins stand at an impressive 93%, showcasing a solid financial foundation.
- 05Truist believes Genmab's capabilities will enable continued long-term value creation despite current market fluctuations.
Advertisement
In-Article Ad
Truist Securities has initiated coverage on Genmab A/S (NASDAQ:GMAB) with a Buy rating and a revised price target of $40, down from $48. The stock is currently trading at $26.89, indicating substantial upside potential. Truist's investment thesis emphasizes Genmab's shift towards a commercially driven model, with three lead assets poised for significant developments by 2026. Key outcomes from Epkinly's DLBCL-2 and DLBCL-4 trials are seen as crucial for expanding the franchise. Additionally, Rina-S and petosemtamab are positioned as potential best-in-class treatments for ovarian cancer and head and neck squamous cell carcinoma, respectively. Genmab's financial health is robust, highlighted by a 93% gross profit margin and a 21% revenue growth over the past year. Recent earnings reports also reflect a 25% revenue increase in Q1 2026, primarily from strong sales of proprietary medicines and royalty streams. Analysts suggest the stock is currently undervalued, reinforcing Genmab's strategic investments and market positioning as it navigates broader market conditions.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
What do you think about Genmab's future performance?
Connecting to poll...
More about Truist Securities
Abivax : Confiance des analystes renforcée après résultats financiers et essais cliniques
Investing French • May 26, 2026
Stifel élève la note de Booz Allen Hamilton malgré une révision à la baisse de l'objectif de prix
Investing French • May 26, 2026
Analyse SWOT d'Olin Corporation : Perspectives contrastées dans un secteur en mutation
Investing French • May 25, 2026
Read the original article
Visit the source for the complete story.